Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company ...
Lung cancer rising among non-smokers — here's why
The most common form of lung cancer is primarily found in non-smokers, a new study reveals. Doctors react to the surprising ...
Merus N.V.: Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length mult ...
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the ...
Merus’ petosemtamab granted Breakthrough Therapy designation by FDA
Merus (MRUS) announced that the FDA has granted Breakthrough Therapy designation to petosemtamab in combination with pembrolizumab for the ...
The Pharma Letter13h
Purple Biotech advances NT219 into Phase II head and neck cancer study
Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...
Irish Independent on MSN3h
Ask the doctor: I have a strange growth on my eyelid – should I be concerned?
Question: I recently noticed a strange growth on my bottom eyelid. It isn’t coming out of a hair follicle, and it isn’t a ...
7MRUS : Merus Shares Are Up Today: What's Going On?
Shares of Merus N.V. (NASDAQ: MRUS) are trading higher Tuesday after the company announced that the U.S. Food and Drug ...
E!13h
Teddi Mellencamp’s Sister Shares Update After Emergency Brain Tumor Surgery
After Teddi Mellencamp underwent emergency brain surgery for her tumors, the Real Housewives of Beverly Hills star’s sister Justice Mellencamp shared an update on her recovery.
Purple Biotech Ltd.: Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab ...
Targeted Oncology12h
FDA Fast-Tracks IBI363 in Squamous NSCLC
The FDA granted fast track status to IBI363 for the treatment of patients with advanced squamous lung cancer after prior ...
Le Lézard16h
CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks
CEL-SCI Corporation today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments. "CEL-SCI is very uniquely positioned at this ...